Gene info: ID 5604

Gene: MAP2K1

GENE ID: 5604

Synonyms: CFC3|MAPKK1|MEK1|MKK1|PRKMK1

Description: mitogen-activated protein kinase kinase 1

Gene type: protein-coding

Location: 15q22.31

dbXrefs: Ensembl:ENSG00000169032 MIM:176872 Vega:OTTHUMG00000133196 UniprotKB:Q02750

RefSeq: NG_008305.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 8

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 2.676e-1 (AD) 6.922e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RNF41	0.965
PCMT1	0.963
NECAP1	0.96
YWHAG	0.96
NAPG	0.959
UBQLN1	0.957
OLA1	0.957
ATP6V1B2	0.957
HSDL1	0.957
FAM220A	0.957

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.593
OR4F29	-0.55
ASB4	-0.422
CSAG1	-0.416
FZD10	-0.403
MTRNR2L6	-0.384
MTRNR2L10	-0.38
KLRB1	-0.376
EBF1	-0.376
MTRNR2L9	-0.374

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB02152	K-252a	Small Molecule	97161-97-2	Experimental	Target
DB03115	5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide	Small Molecule		Experimental	Target
DB05239	Cobimetinib	Small Molecule	934660-93-2	Approved\|Investigational	Target
DB06616	Bosutinib	Small Molecule	380843-75-4	Approved	Target
DB06892	(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide	Small Molecule		Experimental	Target
DB07046	2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide	Small Molecule		Experimental	Target
DB07101	PD-0325901	Small Molecule	391210-10-9	Investigational	Target
DB08130	N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine	Small Molecule		Experimental	Target
DB08208	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Small Molecule		Experimental	Target
DB08911	Trametinib	Small Molecule	871700-17-3	Approved	Target

ID	Drug Name	Action	PubMed
C471674	10'(Z),13'(E),15'(E)-heptadecatrienylhydroquinone	"10'(Z),13'(E),15'(E)-heptadecatrienylhydroquinone results in increased expression of MAP2K1 mRNA"	23088786
C070379	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	"1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]"	11858940
C049325	1,2-dithiol-3-thione	"1,2-dithiol-3-thione results in decreased expression of MAP2K1 mRNA"	19162173
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	"[N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of MAP2K1 protein"	23029544
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein	15817663
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]]	20615082
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dasatinib results in increased phosphorylation of MAP2K1 protein]	23825585
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]	15466214
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	20615082
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein	15179185\|1518404
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [cobaltous chloride results in increased activity of [MAPK1 protein co-treated with MAPK3 protein]]	14536030
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Doxorubicin results in increased cleavage of CASP9 protein]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]	18594523
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Reactive Oxygen Species]	16945329
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PPARG protein]	16945329
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] which results in decreased susceptibility to cobaltous chloride	14536030
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	11858940
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA]	23237828
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein	12663507
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein	11028503\|1453603
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased expression of MAP2K1 mRNA"	25575267
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide results in decreased activity of MAP2K1 protein"	18393446
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [RAF1 protein results in increased activity of MAP2K1 protein]"	10998351
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide results in decreased activity of MAP2K1 protein"	10998351
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]"	12411397
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]"	12411397
C120227	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	"2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide results in decreased activity of MAP2K1 protein"	16261397\|1646720
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of MAP2K1 mRNA"	19114083
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	MAP2K1 protein inhibits the reaction [[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP3 protein]	15850772
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]	12411397
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]	12411397
C506698	2,5-dimethylcelecoxib	"2,5-dimethylcelecoxib inhibits the reaction [IL6 protein results in increased phosphorylation of MAP2K1 protein]"	16123214
C506698	2,5-dimethylcelecoxib	"2,5-dimethylcelecoxib results in decreased phosphorylation of MAP2K1 protein"	16123214
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of MAP2K1 mRNA"	21346803
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAP2K1 protein"	22307971
C014970	2-aminodiphenyl	MAP2K1 protein promotes the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]	22288910
C030370	2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone	"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of MAP2K1 mRNA"	20206263
C473468	3,5,3',4',5'-pentahydroxy-stilbene	"3,5,3',4',5'-pentahydroxy-stilbene binds to MAP2K1 protein"	18767048
C473468	3,5,3',4',5'-pentahydroxy-stilbene	"3,5,3',4',5'-pentahydroxy-stilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]"	18767048
C496751	4-(1H-imidazol-1-yl)retinoic acid	4-(1H-imidazol-1-yl)retinoic acid results in decreased expression of MAP2K1 protein	17145897
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]"	10564177
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [sodium arsenite results in increased phosphorylation of MAP2K1 protein]"	10564177
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [vanadyl sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
C486184	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	"4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of MAP2K1 mRNA"	25575267
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone co-treated with Benzo(a)pyrene] results in increased phosphorylation of MAP2K1 protein	21882252
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	Catechin inhibits the reaction [[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone co-treated with Benzo(a)pyrene] results in increased phosphorylation of MAP2K1 protein]	21882252
C489251	5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone	"5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone results in increased phosphorylation of MAP2K1 protein"	19167484
C010643	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	"6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]"	16510265
C054852	7-hydroxystaurosporine	[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein	15767555
C054852	7-hydroxystaurosporine	[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein	15767555
C072876	A 771726	A 771726 inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein]	9973483
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	18703135
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	18703135
D020106	Acrylamide	Acrylamide results in increased expression of MAP2K1 mRNA	28959563
D000255	Adenosine Triphosphate	Adenosine Triphosphate binds to MAP2K1 protein	17693661
C016601	afimoxifene	afimoxifene results in increased expression of MAP2K1 mRNA	12154049
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of MAP2K1 mRNA	27153756
C412373	AG 1879	AG 1879 inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]	16510265
D013196	Dihydrotestosterone	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
D013196	Dihydrotestosterone	bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15466214
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of MAP2K1 mRNA	16483693
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of MAP2K1 mRNA	12420312
C078814	anandamide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C078814	anandamide	anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein	12657697
C078814	anandamide	U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C006578	anethole	anethole inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein]	10871845
C031385	anthranilic acid	anthranilic acid results in decreased activity of MAP2K1 protein	18393446
C030325	anthrax toxin	anthrax toxin results in increased cleavage of MAP2K1 protein	24337744
D000935	Antifungal Agents	Antifungal Agents inhibits the reaction [MAP2K1 protein results in increased phosphorylation of MAPK1 protein]	21217783
D000935	Antifungal Agents	Antifungal Agents inhibits the reaction [MAP2K1 protein results in increased phosphorylation of MAPK3 protein]	21217783
D000935	Antifungal Agents	MAP2K1 protein results in decreased susceptibility to Antifungal Agents	21217783
D016718	Arachidonic Acid	FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]	19720122
D016718	Arachidonic Acid	FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]	19720122
D016718	Arachidonic Acid	MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]	19720122
D016718	Arachidonic Acid	MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]	19720122
C025657	arsenic acid	arsenic acid results in increased activity of MAP2K1 protein	14674888
C006632	arsenic trioxide	arsenic trioxide results in increased activity of MAP2K1 protein	15093545
C006632	arsenic trioxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]]	20615082
C006632	arsenic trioxide	arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	20615082
C006632	arsenic trioxide	arsenic trioxide results in decreased activity of MAP2K1 protein	11304686
C006632	arsenic trioxide	arsenic trioxide results in decreased phosphorylation of MAP2K1 protein	20592496
C006632	arsenic trioxide	arsenic trioxide results in increased expression of MAP2K1 mRNA	22521957
C006632	arsenic trioxide	arsenic trioxide results in increased phosphorylation of and results in increased activity of MAP2K1 protein	20615082
C006632	arsenic trioxide	arsenic trioxide results in decreased phosphorylation of MAP2K1 protein	28454374
C006632	arsenic trioxide	MAP2K1 protein promotes the reaction [arsenic trioxide results in decreased phosphorylation of JUN protein]	21278055
C006632	arsenic trioxide	MAP2K1 protein promotes the reaction [arsenic trioxide results in increased expression of CDKN1A protein]	21278055
C006632	arsenic trioxide	MAP2K1 protein promotes the reaction [arsenic trioxide results in increased phosphorylation of GSK3B protein]	21278055
C015001	arsenite	arsenite results in increased activity of MAP2K1 protein	14674888
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite affects the expression of MAP2K1 mRNA"	24160326
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in increased phosphorylation of MAP2K1 protein"	18314537
D017638	Asbestos, Crocidolite	"MAP2K1 protein affects the reaction [Asbestos, Crocidolite results in increased expression of SCGB1A1 mRNA]"	18192500
D017638	Asbestos, Crocidolite	"MAP2K1 protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]"	18192500
D017638	Asbestos, Crocidolite	"MAP2K1 protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]"	18192500
D017638	Asbestos, Crocidolite	"MAP2K1 protein inhibits the reaction [Asbestos, Crocidolite results in increased expression of COL1A1 mRNA]"	18192500
D017638	Asbestos, Crocidolite	"MAP2K1 protein inhibits the reaction [Asbestos, Crocidolite results in increased expression of COL3A1 mRNA]"	18192500
D017638	Asbestos, Crocidolite	"MAP2K1 protein inhibits the reaction [Asbestos, Crocidolite results in increased expression of IL6 mRNA]"	18192500
D001241	Aspirin	Aspirin results in increased expression of MAP2K1 mRNA	20457246
D001280	Atrazine	Atrazine results in decreased expression of MAP2K1 mRNA	25929836
D001379	Azathioprine	Azathioprine results in decreased phosphorylation of MAP2K1 protein	12697733
C517975	AZD 6244	AZD 6244 results in decreased activity of MAP2K1 protein	23587417
C547126	AZM551248	AZM551248 results in increased expression of MAP2K1 mRNA	22323515
D001564	Benzo(a)pyrene	[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone co-treated with Benzo(a)pyrene] results in increased phosphorylation of MAP2K1 protein	21882252
D001564	Benzo(a)pyrene	Catechin inhibits the reaction [[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone co-treated with Benzo(a)pyrene] results in increased phosphorylation of MAP2K1 protein]	21882252
D001564	Benzo(a)pyrene	AHR protein affects the reaction [Benzo(a)pyrene affects the expression of MAP2K1 mRNA]	22228805
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of MAP2K1 mRNA	22228805
C035982	beryllium fluoride	beryllium fluoride results in increased phosphorylation of MAP2K1 protein	11867686
D004958	Estradiol	Estradiol results in increased activity of MAP2K1 protein	15615701
D004958	Estradiol	Estradiol affects the expression of MAP2K1 mRNA	22574217
D004958	Estradiol	Estradiol results in increased activity of MAP2K1 protein	15615701
D004958	Estradiol	Estradiol results in increased expression of MAP2K1 mRNA	12154049\|2309414
D004958	Estradiol	IGF1R mutant form inhibits the reaction [Estradiol results in increased expression of MAP2K1 mRNA]	23094148
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in increased expression of MAP2K1 mRNA]	25210133
D004958	Estradiol	Estradiol affects the expression of MAP2K1 mRNA	15598610
D004958	Estradiol	Estradiol results in increased expression of MAP2K1 mRNA	14664709\|2521013
C044887	beta-methylcholine	beta-methylcholine affects the expression of MAP2K1 mRNA	21179406
C053541	bicalutamide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
C053541	bicalutamide	bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	15466214
C053541	bicalutamide	bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15466214
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	11861786
C006780	bisphenol A	bisphenol A results in decreased expression of MAP2K1 mRNA	29275510
C006780	bisphenol A	bisphenol A results in increased expression of MAP2K1 mRNA	25575267
C006780	bisphenol A	bisphenol A affects the expression of MAP2K1 mRNA	21786754
C006780	bisphenol A	bisphenol A results in increased expression of MAP2K1 mRNA	25181051
D000069286	Bortezomib	[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein	12893773
D000069286	Bortezomib	[Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein	12893773
D002087	Butyrates	[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein	12893773
D002087	Butyrates	Butyrates results in decreased expression of MAP2K1 protein	12893773
D002087	Butyrates	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]	15781658
D002104	Cadmium	Cadmium results in increased activity of MAP2K1 protein	20153348
D002104	Cadmium	Cadmium results in increased phosphorylation of MAP2K1 protein	14499349
D002104	Cadmium	GPER1 mutant form inhibits the reaction [Cadmium results in increased activity of MAP2K1 protein]	20153348
D002104	Cadmium	MAP2K1 protein affects the reaction [Cadmium results in increased expression of PLAUR mRNA]	25069788
C028031	cadmium acetate	cadmium acetate affects the expression of MAP2K1 mRNA	16249259
D019256	Cadmium Chloride	Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	18703135
D019256	Cadmium Chloride	Cadmium Chloride results in increased phosphorylation of MAP2K1 protein	18703135
D019256	Cadmium Chloride	"1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]"	11858940
D019256	Cadmium Chloride	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	11858940
D019256	Cadmium Chloride	Cadmium Chloride results in increased phosphorylation of MAP2K1 protein	11858940
D019256	Cadmium Chloride	U 0126 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	11858940
D019256	Cadmium Chloride	Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	18703135
D019256	Cadmium Chloride	Cadmium Chloride results in increased phosphorylation of MAP2K1 protein	18703135
D019256	Cadmium Chloride	MAP2K1 protein mutant form promotes the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein]	23876460
D000001	Calcimycin	Calcimycin results in increased phosphorylation of and results in increased activity of MAP2K1 protein	16000378
D002118	Calcium	Calcium inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]	12574409
D002118	Calcium	[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]	12574409
D002211	Capsaicin	Capsaicin results in increased expression of MAP2K1 mRNA	19502594
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of MAP2K1 mRNA	17805973
D002392	Catechin	Catechin inhibits the reaction [[4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone co-treated with Benzo(a)pyrene] results in increased phosphorylation of MAP2K1 protein]	21882252
D002392	Catechin	Catechin results in decreased expression of MAP2K1 mRNA	15465739
D002392	Catechin	Catechin results in decreased expression of MAP2K1 protein	15465739
D002392	Catechin	Catechin results in increased expression of MAP2K1 mRNA	15465739
D000068579	Celecoxib	Celecoxib results in decreased phosphorylation of MAP2K1 protein	16123214
D000068579	Celecoxib	Celecoxib results in decreased expression of MAP2K1 mRNA	28201806
D000068579	Celecoxib	Celecoxib results in increased expression of MAP2K1 mRNA	28201806
D002713	Chlorine	Chlorine results in increased expression of MAP2K1 mRNA	18636392
D002713	Chlorine	[Ozone co-treated with Chlorine] results in decreased expression of MAP2K1 mRNA	18636392
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of MAP2K1 mRNA	23650126
C100187	chloropicrin	chloropicrin results in decreased expression of MAP2K1 mRNA	28476498
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of MAP2K1 mRNA	18668222
D002794	Choline	Choline inhibits the reaction [Sodium Fluoride results in decreased expression of MAP2K1 mRNA]	27664006
D002794	Choline	Choline results in increased expression of MAP2K1 mRNA	27664006
C011585	ciclopirox	ciclopirox inhibits the reaction [MAP2K1 protein results in increased phosphorylation of MAPK1 protein]	21217783
C011585	ciclopirox	ciclopirox inhibits the reaction [MAP2K1 protein results in increased phosphorylation of MAPK3 protein]	21217783
C011585	ciclopirox	MAP2K1 protein results in decreased susceptibility to ciclopirox	21217783
C503589	cis-9, trans-11-conjugated linoleic acid	"[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein"	17869086
C503589	cis-9, trans-11-conjugated linoleic acid	"cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K1 protein"	17869086
C488583	Clostridium difficile lethal toxin B	Clostridium difficile lethal toxin B inhibits the reaction [EDN1 protein results in increased phosphorylation of MAP2K1 protein]	11158304
D003024	Clozapine	Clozapine results in decreased expression of MAP2K1 mRNA	15860345
C018021	cobaltous chloride	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [cobaltous chloride results in increased activity of [MAPK1 protein co-treated with MAPK3 protein]]	14536030
C018021	cobaltous chloride	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] which results in decreased susceptibility to cobaltous chloride	14536030
C018021	cobaltous chloride	cobaltous chloride results in increased expression of MAP2K1 mRNA	19376846
C018021	cobaltous chloride	cobaltous chloride results in increased expression of MAP2K1 mRNA	24386269
D003042	Cocaine	Cocaine results in decreased expression of MAP2K1 mRNA	12629581
D003042	Cocaine	Cocaine results in increased expression of MAP2K1 mRNA	11299316
D003042	Cocaine	Cocaine results in increased expression of MAP2K1 protein	11299316
D003042	Cocaine	CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of MAP2K1 protein]	15665076
D003042	Cocaine	Cocaine results in increased phosphorylation of MAP2K1 protein	15665076
D003300	Copper	Copper binds to and results in decreased activity of MAP2K1 protein	24717435
D003300	Copper	[Copper binds to and results in decreased activity of MAP2K1 protein] which results in decreased activity of MAP2K2 protein	24717435
D003300	Copper	Copper binds to MAP2K1 protein mutant form	24717435
D003300	Copper	Copper promotes the reaction [MAP2K1 protein results in increased phosphorylation of MAPK1 protein]	24717435
D019327	Copper Sulfate	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Copper Sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
D019327	Copper Sulfate	Copper Sulfate results in increased expression of MAP2K1 mRNA	19549813
D019327	Copper Sulfate	Copper Sulfate results in increased phosphorylation of and results in increased activity of MAP2K1 protein	10564177
D016578	Crack Cocaine	Crack Cocaine results in increased expression of MAP2K1 mRNA	12629581
C015763	cumene	[cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 mRNA	18648096
C015763	cumene	[cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 protein	18648096
D003474	Curcumin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]]	21810436
D003474	Curcumin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]]	21810436
D003474	Curcumin	MAP2K1 results in decreased susceptibility to [Curcumin co-treated with Mitomycin]	21810436
D003513	Cycloheximide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA]	23237828
D003513	Cycloheximide	Cycloheximide results in increased activity of MAP2K1 protein	23237828
D016572	Cyclosporine	Cyclosporine results in increased expression of MAP2K1 mRNA	25562108
D000069439	Dasatinib	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dasatinib results in increased phosphorylation of MAP2K1 protein]	23825585
D000069439	Dasatinib	Dasatinib results in increased phosphorylation of MAP2K1 protein	23825585
C014347	decitabine	decitabine results in increased expression of MAP2K1 mRNA	17785578
C107676	deguelin	deguelin metabolite results in decreased expression of MAP2K1 protein	19139008
C107676	deguelin	deguelin results in decreased expression of MAP2K1 protein	19139008\|1933672
D003847	Deoxyglucose	MAP2K1 protein results in decreased susceptibility to Deoxyglucose	16701555
D003847	Deoxyglucose	U 0126 inhibits the reaction [MAP2K1 protein results in decreased susceptibility to Deoxyglucose]	16701555
D003907	Dexamethasone	Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]	10807665
D003907	Dexamethasone	Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]]	10807665
D003907	Dexamethasone	Dexamethasone results in increased expression of MAP2K1 mRNA	21041162
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of MAP2K1 mRNA	21266533
D002945	Cisplatin	[Cisplatin co-treated with Quercetin] results in increased expression of MAP2K1 mRNA	27514524
D002945	Cisplatin	Cisplatin results in increased phosphorylation of MAP2K1 protein	21444628
D002945	Cisplatin	MAP2K1 protein results in decreased susceptibility to [Cisplatin co-treated with Fluorouracil]	21444628
D002945	Cisplatin	[U 0126 results in decreased activity of MAP2K1 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin]	21444628
D002945	Cisplatin	MAP2K1 protein promotes the reaction [Cisplatin results in increased activity of CASP3 protein]	20547441
D002945	Cisplatin	MAP2K1 protein promotes the reaction [Cisplatin results in increased phosphorylation of SHC1 protein]	20547441
D004026	Dieldrin	Dieldrin results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15888667
D004052	Diethylnitrosamine	Diethylnitrosamine affects the phosphorylation of MAP2K1 protein	24535843
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of MAP2K1 mRNA	15766595
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of MAP2K1 mRNA	16636312\|2557526
D004147	Dioxins	Dioxins affects the expression of MAP2K1 mRNA	20463971
C493087	diphenylarsinic acid	diphenylarsinic acid results in increased phosphorylation of and results in increased expression of MAP2K1 protein	28087833
C493087	diphenylarsinic acid	U 0126 inhibits the reaction [diphenylarsinic acid results in increased expression of MAP2K1 protein]	28087833
D004317	Doxorubicin	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]	18594523
D004317	Doxorubicin	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]	18594523
D004317	Doxorubicin	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Doxorubicin results in increased cleavage of CASP9 protein]	18594523
D004317	Doxorubicin	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]	18594523
D004317	Doxorubicin	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]	18594523
D004317	Doxorubicin	Doxorubicin results in increased phosphorylation of MAP2K1 protein	17974986
D004317	Doxorubicin	Doxorubicin results in increased phosphorylation of MAP2K1 protein	17974986
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal results in increased phosphorylation of MAP2K1 protein"	28733231
D004642	Emodin	Emodin inhibits the reaction [PDGFB protein results in increased phosphorylation of MAP2K1 protein]	15288473
D004726	Endosulfan	Endosulfan results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15888667
C074283	estradiol 3-benzoate	estradiol 3-benzoate results in decreased phosphorylation of MAP2K1 protein	15778002
D004964	Estriol	Estriol results in increased expression of MAP2K1 mRNA	25575267
D004976	Ethacrynic Acid	Ethacrynic Acid results in increased expression of MAP2K1 protein	14556662
D000431	Ethanol	Ethanol affects the expression of MAP2K1 mRNA	11772933
D000431	Ethanol	Ethanol results in decreased expression of MAP2K1 mRNA	20655511
D000431	Ethanol	Ethanol results in increased expression of MAP2K1 protein	23702218
D000431	Ethanol	"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of MAP2K1 mRNA]"	20655511
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of MAP2K1 mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MAP2K1 mRNA	17108234
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in decreased expression of MAP2K1 mRNA	23649840
C082360	fipronil	fipronil results in decreased activity of MAP2K1 protein	21167920
D005419	Flavonoids	Flavonoids results in decreased expression of MAP2K1 mRNA	15465739
C024352	fludarabine	fludarabine results in increased activity of MAP2K1 protein	15059916
C024352	fludarabine	MAP2K1 protein inhibits the reaction [[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP3 protein]	15850772
D005472	Fluorouracil	MAP2K1 protein results in decreased susceptibility to [Cisplatin co-treated with Fluorouracil]	21444628
D005472	Fluorouracil	[U 0126 results in decreased activity of MAP2K1 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin]	21444628
D005485	Flutamide	Flutamide results in increased expression of MAP2K1 mRNA	24136188
D005707	Gallic Acid	Gallic Acid inhibits the reaction [TNF protein results in increased phosphorylation of MAP2K1 protein]	21420233
D005707	Gallic Acid	MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased expression of MMP9 protein]]	27634460
D005707	Gallic Acid	MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of JUN protein]]	27634460
D005707	Gallic Acid	[MAP2K1 protein modified form co-treated with AKT1 protein modified form] inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased expression of MMP9 protein]]	27087131
D005707	Gallic Acid	[MAP2K1 protein modified form co-treated with AKT1 protein modified form] inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of JUN protein]]	27087131
D005707	Gallic Acid	[MAP2K1 protein modified form co-treated with AKT1 protein modified form] inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]]	27087131
C574276	GDC-0973	GDC-0973 results in decreased activity of MAP2K1 protein	22084396\|2358741
C001277	geldanamycin	geldanamycin results in decreased phosphorylation of MAP2K1 protein	19167484
C001277	geldanamycin	geldanamycin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]	8816498
D019833	Genistein	Genistein results in increased phosphorylation of MAP2K1 protein	19038232
D019833	Genistein	Genistein results in decreased phosphorylation of MAP2K1 protein	15781664
C094503	glyceryl 2-arachidonate	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C094503	glyceryl 2-arachidonate	glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein	12657697
C094503	glyceryl 2-arachidonate	U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
D006046	Gold	MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased expression of MMP9 protein]]	27634460
D006046	Gold	MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of JUN protein]]	27634460
D006152	Cyclic GMP	Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]	18225537
D006152	Cyclic GMP	Cyclic GMP results in decreased phosphorylation of MAP2K1 protein	18225537
D019307	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein	14654170
D019307	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K1 protein	14654170
D006220	Haloperidol	Haloperidol results in decreased expression of MAP2K1 mRNA	15860345
D006493	Heparin	Heparin results in decreased activity of MAP2K1 protein	9546238
D006493	Heparin	Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein]	14966081
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]	14966081
D006533	Heptachlor	Heptachlor results in decreased expression of MAP2K1 protein	9704902
D006533	Heptachlor	Heptachlor results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15888667
D006820	Hyaluronic Acid	Hyaluronic Acid analog results in increased phosphorylation of MAP2K1 protein	12402308
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased activity of MAP2K1 protein	15242773\|1903823
D006861	Hydrogen Peroxide	MAP2K1 protein affects the reaction [Hydrogen Peroxide results in increased expression of MMP9 mRNA]	26514923
C107079	hymenialdisine	hymenialdisine results in decreased activity of MAP2K1 protein	21615147
C078038	inchinko-to	inchinko-to inhibits the reaction [PDGFB protein results in increased phosphorylation of MAP2K1 protein]	15288473
D007213	Indomethacin	Indomethacin results in increased expression of MAP2K1 mRNA	18299717
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MAP2K1 mRNA	25613284
D015759	Ionomycin	Ionomycin inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]	12574409
D015056	1-Methyl-3-isobutylxanthine	[FSHB protein co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]]	21177760
D007545	Isoproterenol	MAP2K1 protein promotes the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]	21177286
D007545	Isoproterenol	MAP2K1 protein promotes the reaction [Isoproterenol results in decreased expression of COL2A1 protein]	21177286
D007545	Isoproterenol	MAP2K1 protein promotes the reaction [Isoproterenol results in increased phosphorylation of MAPK1 protein]	21177286
D007545	Isoproterenol	MAP2K1 protein promotes the reaction [Isoproterenol results in increased phosphorylation of MAPK3 protein]	21177286
D007545	Isoproterenol	MAP2K1 protein affects the reaction [Isoproterenol results in increased expression of NPPA mRNA]	10888249
D007545	Isoproterenol	MAP2K1 protein affects the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of MAPK1 protein]	10888249
D007545	Isoproterenol	MAP2K1 protein affects the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of MAPK3 protein]	10888249
D007649	Ketamine	Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	19540866
D007854	Lead	Lead results in increased phosphorylation of MAP2K1 protein	19133285
D007854	Lead	Lead results in decreased expression of MAP2K1 mRNA	24960059
D007854	Lead	Lead results in decreased expression of MAP2K1 protein	24960059
C008261	lead acetate	bisindolylmaleimide I inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	11861786
C008261	lead acetate	lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein	11861786
C008261	lead acetate	Tetradecanoylphorbol Acetate inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	11861786
C067431	letrozole	letrozole results in increased expression of MAP2K1 protein	15967659
D001556	Lindane	Lindane results in increased phosphorylation of and results in increased activity of MAP2K1 protein	15888667
C433788	lipopolysaccharide, E. coli O26-B6	"lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of MAP2K1 protein"	21474333
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased phosphorylation of MAP2K1 protein	19010997
D008070	Lipopolysaccharides	MAP2K1 protein mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]	18209571
D008070	Lipopolysaccharides	Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	19540866
D008070	Lipopolysaccharides	[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAP2K1 protein	23362215
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of MAP2K1 mRNA	10975854
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAP2K1 protein	19540866
D008070	Lipopolysaccharides	MAP2K1 protein promotes the reaction [Lipopolysaccharides inhibits the reaction [TGFB1 protein results in increased expression of SMAD6 mRNA]]	21295571
D008070	Lipopolysaccharides	MAP2K1 protein promotes the reaction [Lipopolysaccharides results in increased phosphorylation of SMAD3 protein]	21295571
D008070	Lipopolysaccharides	wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAP2K1 protein]	23362215
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of MAP2K1 mRNA	25613284
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased phosphorylation of MAP2K1 protein	21247645
D008070	Lipopolysaccharides	MAP2K1 protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]	10469353
D008070	Lipopolysaccharides	MAP2K1 protein promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]	10469353
D008070	Lipopolysaccharides	rosiglitazone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAP2K1 protein]	21247645
D008070	Lipopolysaccharides	MAP2K1 protein mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]	18824136
C009900	lipoteichoic acid	lipoteichoic acid results in increased phosphorylation of MAP2K1 protein	19573522
C009900	lipoteichoic acid	Propofol inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAP2K1 protein]	19573522
D008094	Lithium	[Lithium results in increased phosphorylation of and results in increased activity of MAP3K8 protein] which results in increased phosphorylation of MAP2K1 protein	19159680
D008095	Lithocholic Acid	MAP2K1 protein promotes the reaction [Lithocholic Acid results in increased expression of PLAUR mRNA]	19782465
C015329	lycopene	lycopene results in increased expression of MAP2K1 mRNA	16886892
D008344	Maneb	[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA	23963992
D008344	Maneb	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
D008344	Maneb	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
C501277	Mangifera indica extract	Mangifera indica extract inhibits the reaction [TNF protein results in increased phosphorylation of MAP2K1 protein]	21420233
D008353	Mannitol	Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]	16510265
D008550	Melatonin	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
D015122	Mercaptopurine	Mercaptopurine results in decreased phosphorylation of MAP2K1 protein	12697733
D008694	Methamphetamine	Methamphetamine results in decreased expression of MAP2K1 protein	16192988
D008694	Methamphetamine	Methamphetamine results in increased expression of MAP2K1 protein	19826936
C014659	methyl(acetoxymethyl)nitrosamine	methyl(acetoxymethyl)nitrosamine results in increased phosphorylation of and results in increased activity of MAP2K1 protein	12693035
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of MAP2K1 mRNA	25926378
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of MAP2K1 mRNA	23458150
C004925	methylmercuric chloride	methylmercuric chloride affects the expression of MAP2K1 mRNA	21613230
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of MAP2K1 protein	26558463
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of MAP2K1 mRNA	26011545
D008770	Methylnitrosourea	Methylnitrosourea results in increased phosphorylation of and results in increased activity of MAP2K1 protein	12693035
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of MAP2K1 protein	26558463
C008493	methylselenic acid	methylselenic acid results in decreased expression of MAP2K1 mRNA	11830524
C008493	methylselenic acid	methylselenic acid results in increased expression of MAP2K1 mRNA	12517777
D015735	Mifepristone	Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]]	10807665
D016685	Mitomycin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK1 protein]]	21810436
D016685	Mitomycin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased phosphorylation of MAPK3 protein]]	21810436
D016685	Mitomycin	MAP2K1 results in decreased susceptibility to [Curcumin co-treated with Mitomycin]	21810436
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of MAP2K1 mRNA	20886546
D009151	Mustard Gas	Mustard Gas results in increased expression of MAP2K1 mRNA	18955075
C040015	myricetin	myricetin binds to and results in decreased activity of MAP2K1 protein	17693661
C040015	myricetin	myricetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]	17693661
C544830	N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide	"N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide results in decreased activity of MAP2K1 protein"	23587417
C068836	N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime	"[N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of MAP2K1 protein"	23029544
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of MAP2K1 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of MAP2K1 mRNA"	25554681
C051752	nefazodone	nefazodone results in increased expression of MAP2K1 mRNA	24136188
C022838	nickel chloride	nickel chloride affects the expression of MAP2K1 mRNA	22110744
D009538	Nicotine	MAP2K1 protein affects the reaction [Nicotine results in increased expression of PLAUR mRNA]	22261521
D009605	Nitrosomethylurethane	Nitrosomethylurethane results in increased phosphorylation of and results in increased activity of MAP2K1 protein	12693035
C520612	N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid	"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of MAP2K1 mRNA]"	20655511
C002741	N-nitrosomorpholine	N-nitrosomorpholine results in increased expression of MAP2K1 protein	21411721
C404397	NSC 680410	NSC 680410 affects the cleavage of MAP2K1 protein	14647418
C404397	NSC 680410	NSC 680410 results in decreased phosphorylation of MAP2K1 protein	14647418
C474958	O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate	"[U 0126 results in decreased activity of MAP2K1 protein] which results in decreased susceptibility to O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"	21849924
C025589	ochratoxin A	ochratoxin A results in increased phosphorylation of MAP2K1 protein	25002221
C474055	octylphenol	octylphenol results in increased activity of MAP2K1 protein	18417718
C474055	octylphenol	U 0126 inhibits the reaction [octylphenol results in increased activity of MAP2K1 protein]	18417718
C440229	Oleylethanolamide	Oleylethanolamide promotes the reaction [ERBB2 protein binds to MAP2K1 protein modified form]	16269455
C440229	Oleylethanolamide	Oleylethanolamide results in increased phosphorylation of MAP2K1 protein	16269455
C440229	Oleylethanolamide	tyrphostin AG 1478 inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K1 protein]	16269455
D010100	Oxygen	MAP2K1 protein results in increased susceptibility to Oxygen	10780954
D010126	Ozone	[Ozone co-treated with Chlorine] results in decreased expression of MAP2K1 mRNA	18636392
D017239	Paclitaxel	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]	18594523
D017239	Paclitaxel	[MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]	18594523
D017239	Paclitaxel	[Tretinoin co-treated with Paclitaxel] results in decreased expression of MAP2K1 protein	18098270
D010269	Paraquat	[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA	23963992
D010269	Paraquat	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
D010269	Paraquat	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
C506614	PD 0325901	PD 0325901 results in decreased activity of MAP2K1 protein	19282848\|2358741
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of MAP2K1 mRNA	23892564
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in increased expression of MAP2K1 mRNA	20136073
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in increased expression of MAP2K1 mRNA	19162173
C105905	perifosine	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]	15781658
C105905	perifosine	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]	15781658
C105905	perifosine	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]	15781658
D010656	Phenylephrine	MAP2K1 protein affects the reaction [Phenylephrine results in increased expression of NPPA mRNA]	10888249
D010656	Phenylephrine	MAP2K1 protein affects the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]	10888249
D010656	Phenylephrine	MAP2K1 protein affects the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]	10888249
D010710	Phosphates	Phosphates results in increased phosphorylation of and results in increased activity of MAP2K1 protein	16763222
C522973	PI103	PI103 results in increased phosphorylation of MAP2K1 protein	21187475
C522973	PI103	[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]	21187475
D010936	Plant Extracts	Plant Extracts results in decreased expression of MAP2K1 mRNA	15465739
D010936	Plant Extracts	Plant Extracts results in increased phosphorylation of MAP2K1 protein	21297082
D010936	Plant Extracts	Plant Extracts binds to and results in decreased activity of MAP2K1 protein	18245498
D059808	Polyphenols	Polyphenols results in decreased expression of MAP2K1 mRNA	15465739
C045950	propiconazole	propiconazole results in increased expression of MAP2K1 mRNA	21278054
D015742	Propofol	Propofol inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAP2K1 protein]	19573522
D015237	Dinoprost	Dinoprost results in increased phosphorylation of MAP2K1 protein	24333336
D015237	Dinoprost	resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]	24333336
D015237	Dinoprost	SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]	24333336
D011710	Pyocyanine	Pyocyanine results in increased phosphorylation of MAP2K1 protein	24015256
D011794	Quercetin	[Cisplatin co-treated with Quercetin] results in increased expression of MAP2K1 mRNA	27514524
D011794	Quercetin	Quercetin binds to and results in decreased activity of MAP2K1 protein	18245498
C037219	quinoline	quinoline results in decreased activity of MAP2K1 protein	18393446
C005266	quinomethionate	quinomethionate affects the expression of MAP2K1 mRNA	15387888
D017382	Reactive Oxygen Species	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Reactive Oxygen Species]	16945329
C059514	resveratrol	resveratrol results in increased activity of MAP2K1 protein	15615701
C059514	resveratrol	MAP2K1 protein inhibits the reaction [resveratrol results in decreased expression of XRCC1 protein]	26046675
C059514	resveratrol	resveratrol results in decreased activity of MAP2K1 protein	15698585
C059514	resveratrol	resveratrol results in decreased phosphorylation of MAP2K1 protein	16761963
C059514	resveratrol	resveratrol results in increased activity of MAP2K1 protein	15615701
C059514	resveratrol	resveratrol results in increased expression of MAP2K1 mRNA	12154049
C059514	resveratrol	resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]	24333336
C577924	RO5126766	RO5126766 results in decreased activity of MAP2K1 protein	23587417
C089730	rosiglitazone	rosiglitazone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAP2K1 protein]	21247645
C085746	rottlerin	rottlerin results in decreased phosphorylation of MAP2K1 protein	15949478
C085746	rottlerin	rottlerin results in decreased phosphorylation of MAP2K1 protein	15949478
C587178	SCH772984	SCH772984 results in increased phosphorylation of MAP2K1 protein	28087833
D017632	Asbestos, Serpentine	"Asbestos, Serpentine affects the expression of MAP2K1 mRNA"	24160326
D012834	Silver	Silver promotes the reaction [MAP2K1 protein results in increased phosphorylation of MAPK1 protein]	24717435
D012838	Silymarin	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]	23963992
D020123	Sirolimus	[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein	15767555
D020123	Sirolimus	[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein	15767555
D020123	Sirolimus	Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]	12411397
D020123	Sirolimus	Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]	12411397
C080703	SK&F 83959	SK&F 83959 results in decreased expression of MAP2K1 protein	25852303
C424127	SL 327	SL 327 results in decreased activity of MAP2K1 protein	20006974
C017947	sodium arsenite	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [sodium arsenite results in increased phosphorylation of MAP2K1 protein]"	10564177
C017947	sodium arsenite	MAP2K1 mutant form inhibits the reaction [sodium arsenite results in increased expression of CDKN1A mRNA]	21642427
C017947	sodium arsenite	MAP2K1 mutant form inhibits the reaction [sodium arsenite results in increased expression of ELK1 mRNA]	21642427
C017947	sodium arsenite	MRAS mutant form inhibits the reaction [sodium arsenite results in increased phosphorylation of MAP2K1 protein]	11943669
C017947	sodium arsenite	sodium arsenite affects the expression of MAP2K1 mRNA	29319823
C017947	sodium arsenite	sodium arsenite affects the expression of MAP2K1 protein modified form	17384772
C017947	sodium arsenite	sodium arsenite results in decreased expression of MAP2K1 mRNA	12016162
C017947	sodium arsenite	sodium arsenite results in increased expression of MAP2K1 mRNA	24431212
C017947	sodium arsenite	sodium arsenite results in increased phosphorylation of and results in increased activity of MAP2K1 protein	10564177
C017947	sodium arsenite	sodium arsenite results in increased phosphorylation of MAP2K1 protein	11943669
C017947	sodium arsenite	sodium arsenite results in increased expression of MAP2K1 protein	28249226
D012969	Sodium Fluoride	Choline inhibits the reaction [Sodium Fluoride results in decreased expression of MAP2K1 mRNA]	27664006
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of MAP2K1 mRNA	27664006
D012969	Sodium Fluoride	Sodium Fluoride results in increased phosphorylation of MAP2K1 protein	19900517
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of MAP2K1 mRNA	16705456
D053260	Soot	[Soot co-treated with Sulfates] affects the methylation of MAP2K1 promoter	25395096
C471405	sorafenib	[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib	20117835
C471405	sorafenib	[MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib	20117835
C471405	sorafenib	[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]	21187475
C471405	sorafenib	sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]	21187475
C471405	sorafenib	sorafenib results in decreased phosphorylation of MAP2K1 protein	17341847\|1820003
C471405	sorafenib	sorafenib results in decreased phosphorylation of MAP2K1 protein	17341847
C525422	SRT1720	SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]	24333336
D013431	Sulfates	[Soot co-treated with Sulfates] affects the methylation of MAP2K1 promoter	25395096
C025462	sulindac sulfide	MAP2K1 protein inhibits the reaction [sulindac sulfide results in decreased phosphorylation of MAPK1 protein]	15548677
C025462	sulindac sulfide	MAP2K1 protein inhibits the reaction [sulindac sulfide results in decreased phosphorylation of MAPK3 protein]	15548677
C025462	sulindac sulfide	MAP2K1 protein inhibits the reaction [sulindac sulfide results in increased cleavage of and results in increased activity of CASP3 protein]	15548677
C025462	sulindac sulfide	MAP2K1 protein promotes the reaction [sulindac sulfide results in increased expression of ATF3 mRNA]	16079301
C025463	sulindac sulfone	MAP2K1 protein inhibits the reaction [sulindac sulfone results in decreased phosphorylation of MAPK1 protein]	15548677
C025463	sulindac sulfone	MAP2K1 protein inhibits the reaction [sulindac sulfone results in decreased phosphorylation of MAPK3 protein]	15548677
C025463	sulindac sulfone	MAP2K1 protein inhibits the reaction [sulindac sulfone results in increased cleavage of and results in increased activity of CASP3 protein]	15548677
D018170	Sumatriptan	Sumatriptan inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]	12574409
D018170	Sumatriptan	[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]	12574409
C558666	TAK 733	TAK 733 results in decreased activity of MAP2K1 protein	23587417
D013629	Tamoxifen	Tamoxifen promotes the reaction [PIN1 protein binds to MAP2K1 protein]	20479004
D013629	Tamoxifen	Tamoxifen results in decreased expression of MAP2K1 protein modified form	17901229
D013629	Tamoxifen	Tamoxifen results in increased expression of MAP2K1 protein modified form	17901229
D013739	Testosterone	[Testosterone results in increased activity of RAF1 protein] which results in increased activity of MAP2K1 protein	20372086
D013739	Testosterone	[FSHB protein co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]]	21177760
D013739	Testosterone	FSHB protein inhibits the reaction [Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]]	21177760
D013739	Testosterone	Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]	21177760
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased activity of MAP2K1 protein	15313166
D013749	Tetrachlorodibenzodioxin	MAP2K1 protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein modified form binds to ARNT protein modified form]]	20450880
D013749	Tetrachlorodibenzodioxin	MAP2K1 protein promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG protein]	12758056
D013749	Tetrachlorodibenzodioxin	MAP2K1 protein promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]	12213569
D013749	Tetrachlorodibenzodioxin	MAP2K1 protein promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of [AHR protein modified form co-treated with ARNT protein modified form]]	20450880
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of MAP2K1 mRNA	21570461
D013755	Tetradecanoylphorbol Acetate	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Reactive Oxygen Species]	16945329
D013755	Tetradecanoylphorbol Acetate	[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PPARG protein]	16945329
D013755	Tetradecanoylphorbol Acetate	MAP2K1 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of PPARG protein]	16945329
D013755	Tetradecanoylphorbol Acetate	PIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAP2K1 protein]	20479004
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	11861786
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased phosphorylation of MAP2K1 protein	20479004
D013755	Tetradecanoylphorbol Acetate	"3,5,3',4',5'-pentahydroxy-stilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]"	18767048
D013755	Tetradecanoylphorbol Acetate	geldanamycin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]	8816498
D013755	Tetradecanoylphorbol Acetate	myricetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]	17693661
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein	17693661\|1876704
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MAP2K1 mRNA	25613284
D015647	2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine	"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of MAP2K1 protein"	25852303
C020809	tetrathiomolybdate	tetrathiomolybdate results in decreased activity of MAP2K1 protein mutant form	24717435
D013974	Thyroxine	Thyroxine results in decreased expression of MAP2K1 mRNA	17403546
C009495	titanium dioxide	titanium dioxide analog results in increased phosphorylation of MAP2K1 protein	25111187
D014028	Tobacco Smoke Pollution	MAP2K1 protein affects the reaction [Tobacco Smoke Pollution results in increased secretion of CXCL8 protein]	22048642
D014050	Toluene	Toluene affects the expression of MAP2K1 mRNA	21827849
C036454	toosendanin	toosendanin results in decreased expression of MAP2K1 protein modified form	23111283
C560077	trametinib	trametinib results in decreased activity of MAP2K1 protein	22733540\|2358741
C496197	trans-10,cis-12-conjugated linoleic acid	"[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein"	17869086
D014212	Tretinoin	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]]	20615082
D014212	Tretinoin	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	20615082
D014212	Tretinoin	arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	20615082
D014212	Tretinoin	[Tretinoin co-treated with Paclitaxel] results in decreased expression of MAP2K1 protein	18098270
D014212	Tretinoin	Tretinoin results in decreased expression of MAP2K1 protein	18098270
D014212	Tretinoin	Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein	20615082
D014212	Tretinoin	Tretinoin results in increased phosphorylation of MAP2K1 protein	19038232
C012589	trichostatin A	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]	15781658
C012589	trichostatin A	trichostatin A affects the expression of MAP2K1 mRNA	28542535
C046488	trimethyltin	trimethyltin results in increased expression of MAP2K1 mRNA	20833246
C057693	troglitazone	MAP2K1 protein promotes the reaction [troglitazone results in increased expression of ATF3 mRNA]	16079301
C101044	tyrphostin AG 1478	tyrphostin AG 1478 inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K1 protein]	16269455
C113580	U 0126	U 0126 results in decreased activity of MAP2K1 protein	15331595\|1554772
C113580	U 0126	[U 0126 results in decreased activity of MAP2K1 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin]	21444628
C113580	U 0126	"[U 0126 results in decreased activity of MAP2K1 protein] which results in decreased susceptibility to O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate"	21849924
C113580	U 0126	[U 0126 binds to MAP2K1 protein] inhibits the reaction [RAF1 protein results in increased activity of MAP2K1 protein]	10998351
C113580	U 0126	U 0126 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K1 protein]	11858940
C113580	U 0126	U 0126 inhibits the reaction [octylphenol results in increased activity of MAP2K1 protein]	18417718
C113580	U 0126	U 0126 inhibits the reaction [RAF1 protein results in increased activity of MAP2K1 protein]	10998351
C113580	U 0126	U 0126 results in decreased activity of MAP2K1 protein	18417718\|2129557
C113580	U 0126	[U 0126 results in decreased activity of MAP2K1 protein] inhibits the reaction [[PDGFA protein binds to PDGFB protein] which results in increased expression of EGR1 protein]	11511524
C113580	U 0126	[U 0126 results in decreased activity of MAP2K1 protein] inhibits the reaction [[PDGFA protein binds to PDGFB protein] which results in increased expression of SOD2 mRNA]	11511524
C113580	U 0126	[U 0126 results in decreased activity of MAP2K1 protein] inhibits the reaction [[PDGFA protein binds to PDGFB protein] which results in increased phosphorylation of MAPK1 protein]	11511524
C113580	U 0126	[U 0126 results in decreased activity of MAP2K1 protein] inhibits the reaction [[PDGFA protein binds to PDGFB protein] which results in increased phosphorylation of MAPK3 protein]	11511524
C113580	U 0126	U 0126 results in decreased activity of MAP2K1 protein	10998351
C113580	U 0126	U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C113580	U 0126	U 0126 inhibits the reaction [diphenylarsinic acid results in increased expression of MAP2K1 protein]	28087833
C113580	U 0126	U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	12657697
C113580	U 0126	U 0126 inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]	12411397
C113580	U 0126	U 0126 inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]	12411397
C113580	U 0126	U 0126 promotes the reaction [NGF protein results in increased phosphorylation of and results in increased activity of MAP2K1 protein]	14713289
C113580	U 0126	U 0126 inhibits the reaction [MAP2K1 protein results in decreased susceptibility to Deoxyglucose]	16701555
C113580	U 0126	U 0126 results in decreased activity of MAP2K1 protein	11511524\|1465417
C113580	U 0126	U 0126 results in decreased phosphorylation of MAP2K1 protein	24782617
D014520	Urethane	Urethane results in increased expression of MAP2K1 mRNA	28818685
D014638	Vanadates	Vanadates results in increased expression of MAP2K1 protein	17874149
C034028	vanadyl sulfate	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [vanadyl sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
C034028	vanadyl sulfate	MRAS mutant form inhibits the reaction [vanadyl sulfate results in increased phosphorylation of MAP2K1 protein]	11943669
C034028	vanadyl sulfate	vanadyl sulfate results in increased phosphorylation of and results in increased activity of MAP2K1 protein	10564177
C034028	vanadyl sulfate	vanadyl sulfate results in increased phosphorylation of MAP2K1 protein	11943669
C459559	vaticanol C	vaticanol C results in decreased expression of and results in decreased phosphorylation of MAP2K1 protein	15725661
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of MAP2K1 gene	25560391
C551177	vemurafenib	MAP2K1 protein mutant form results in decreased susceptibility to vemurafenib	24717435
D014801	Vitamin A	"6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]"	16510265
D014801	Vitamin A	AG 1879 inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]	16510265
D014801	Vitamin A	Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein]	16510265
D014801	Vitamin A	Vitamin A results in increased phosphorylation of MAP2K1 protein	16510265
C111237	vorinostat	[Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein	12893773
C111237	vorinostat	MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]	15781658
C111237	vorinostat	vorinostat results in decreased expression of MAP2K1 protein	12893773
C085514	wogonin	wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAP2K1 protein]	23362215
D019287	Zinc Sulfate	"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAP2K1 protein]"	10564177
D019287	Zinc Sulfate	MRAS mutant form inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAP2K1 protein]	11943669
D019287	Zinc Sulfate	Zinc Sulfate results in increased phosphorylation of and results in increased activity of MAP2K1 protein	10564177
D019287	Zinc Sulfate	Zinc Sulfate results in increased phosphorylation of MAP2K1 protein	11943669

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004672	protein kinase activity	-	IDA	28166211
GO:0004674	protein serine/threonine kinase activity	-	IBA	21873635
GO:0004674	protein serine/threonine kinase activity	-	IMP	18305109
GO:0004674	protein serine/threonine kinase activity	-	TAS	-
GO:0004708	MAP kinase kinase activity	-	IBA	21873635
GO:0004708	MAP kinase kinase activity	-	IDA	8388392
GO:0004712	protein serine/threonine/tyrosine kinase activity	-	TAS	19565474
GO:0004713	protein tyrosine kinase activity	-	IEA	-
GO:0005515	protein binding	-	IPI	10409742 15299019 17110930 17255949 17724343 17979178 18329369 19197339 20179161 20554783 20679487 22752157 23241949 23934108 24211253 24746704 25155755 25416956 25437913 25600339 26496610
GO:0005524	ATP binding	-	IEA	-
GO:0008022	protein C-terminus binding	-	IDA	22572157
GO:0043539	protein serine/threonine kinase activator activity	-	IDA	8388392
GO:0047485	protein N-terminus binding	-	IDA	22572157
GO:0097110	scaffold protein binding	-	IPI	10409742

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000165	MAPK cascade	-	TAS	-
GO:0000187	activation of MAPK activity	-	IBA	21873635
GO:0000187	activation of MAPK activity	-	IDA	10644344
GO:0000187	activation of MAPK activity	-	TAS	19565474
GO:0006468	protein phosphorylation	-	IDA	28166211
GO:0006935	chemotaxis	-	TAS	10570282
GO:0007050	cell cycle arrest	-	IMP	9765203
GO:0007165	signal transduction	-	TAS	10570282
GO:0007346	regulation of mitotic cell cycle	-	IBA	21873635
GO:0007507	heart development	-	IEA	-
GO:0008285	negative regulation of cell proliferation	-	IDA	9765203
GO:0010628	positive regulation of gene expression	-	IMP	15155804
GO:0010629	negative regulation of gene expression	-	IGI	23626836
GO:0018107	peptidyl-threonine phosphorylation	-	IMP	18305109
GO:0018108	peptidyl-tyrosine phosphorylation	-	IEA	-
GO:0021697	cerebellar cortex formation	-	IEA	-
GO:0023014	signal transduction by protein phosphorylation	-	IBA	21873635
GO:0030182	neuron differentiation	-	IBA	21873635
GO:0030182	neuron differentiation	-	IEA	-
GO:0030216	keratinocyte differentiation	-	IEA	-
GO:0030878	thyroid gland development	-	IEA	-
GO:0032147	activation of protein kinase activity	-	IBA	21873635
GO:0032872	regulation of stress-activated MAPK cascade	-	TAS	19565474
GO:0045893	positive regulation of transcription, DNA-templated	-	IMP	24375836 26514923
GO:0048538	thymus development	-	IEA	-
GO:0048679	regulation of axon regeneration	-	IEA	-
GO:0048870	cell motility	-	IEA	-
GO:0050772	positive regulation of axonogenesis	-	IEA	-
GO:0060020	Bergmann glial cell differentiation	-	IEA	-
GO:0060324	face development	-	IEA	-
GO:0060440	trachea formation	-	IEA	-
GO:0060502	epithelial cell proliferation involved in lung morphogenesis	-	IEA	-
GO:0060674	placenta blood vessel development	-	IEA	-
GO:0060711	labyrinthine layer development	-	IEA	-
GO:0070371	ERK1 and ERK2 cascade	-	IMP	18305109
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	IMP	24375836
GO:0071902	positive regulation of protein serine/threonine kinase activity	-	IDA	8388392
GO:0090170	regulation of Golgi inheritance	-	TAS	19565474
GO:0090398	cellular senescence	-	IMP	9765203
GO:1903800	positive regulation of production of miRNAs involved in gene silencing by miRNA	-	IMP	24375836
GO:2000641	regulation of early endosome to late endosome transport	-	TAS	19565474

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	TAS	19565474
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005739	mitochondrion	-	TAS	19565474
GO:0005769	early endosome	-	TAS	19565474
GO:0005770	late endosome	-	TAS	19565474
GO:0005783	endoplasmic reticulum	-	IDA	22572157
GO:0005794	Golgi apparatus	-	TAS	19565474
GO:0005815	microtubule organizing center	-	IEA	-
GO:0005829	cytosol	-	IDA	-
GO:0005829	cytosol	-	TAS	19565474
GO:0005886	plasma membrane	-	IDA	-
GO:0005925	focal adhesion	-	TAS	19565474

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04012	ErbB signaling pathway
hsa04062	Chemokine signaling pathway
hsa04114	Oocyte meiosis
hsa04270	Vascular smooth muscle contraction
hsa04320	Dorso-ventral axis formation
hsa04370	VEGF signaling pathway
hsa04380	Osteoclast differentiation
hsa04510	Focal adhesion
hsa04540	Gap junction
hsa04620	Toll-like receptor signaling pathway
hsa04650	Natural killer cell mediated cytotoxicity
hsa04660	T cell receptor signaling pathway
hsa04662	B cell receptor signaling pathway
hsa04664	Fc epsilon RI signaling pathway
hsa04666	Fc gamma R-mediated phagocytosis
hsa04720	Long-term potentiation
hsa04722	Neurotrophin signaling pathway
hsa04730	Long-term depression
hsa04810	Regulation of actin cytoskeleton
hsa04910	Insulin signaling pathway
hsa04912	GnRH signaling pathway
hsa04914	Progesterone-mediated oocyte maturation
hsa04916	Melanogenesis
hsa05020	Prion diseases
hsa05200	Pathways in cancer
hsa05210	Colorectal cancer
hsa05211	Renal cell carcinoma
hsa05212	Pancreatic cancer
hsa05213	Endometrial cancer
hsa05214	Glioma
hsa05215	Prostate cancer
hsa05216	Thyroid cancer
hsa05218	Melanoma
hsa05219	Bladder cancer
hsa05220	Chronic myeloid leukemia
hsa05221	Acute myeloid leukemia
hsa05223	Non-small cell lung cancer

Reactome ID	Reactome Term	Evidence
R-HSA-110056	MAPK3 (ERK1) activation	TAS
R-HSA-112409	RAF-independent MAPK1/3 activation	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	IEA
R-HSA-166058	MyD88:Mal cascade initiated on plasma membrane	IEA
R-HSA-166166	MyD88-independent TLR4 cascade	IEA
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	IEA
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	IEA
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	IEA
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	IEA
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	IEA
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	IEA
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	IEA
R-HSA-168249	Innate Immune System	IEA
R-HSA-168256	Immune System	IEA
R-HSA-168898	Toll-Like Receptors Cascades	IEA
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	IEA
R-HSA-373760	L1CAM interactions	TAS
R-HSA-422475	Axon guidance	TAS
R-HSA-445144	Signal transduction by L1	TAS
R-HSA-446652	Interleukin-1 family signaling	IEA
R-HSA-448424	Interleukin-17 signaling	IEA
R-HSA-449147	Signaling by Interleukins	IEA
R-HSA-450294	MAP kinase activation	IEA
R-HSA-5210891	Uptake and function of anthrax toxins	TAS
R-HSA-5339562	Uptake and actions of bacterial toxins	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663205	Infectious disease	TAS
R-HSA-5673000	RAF activation	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5674135	MAP2K and MAPK activation	TAS
R-HSA-5674499	Negative feedback regulation of MAPK pathway	TAS
R-HSA-5675221	Negative regulation of MAPK pathway	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684264	MAP3K8 (TPL2)-dependent MAPK1/3 activation	IEA
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	TAS
R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	TAS
R-HSA-6802949	Signaling by RAS mutants	TAS
R-HSA-6802952	Signaling by BRAF and RAF fusions	TAS
R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	TAS
R-HSA-6802957	Oncogenic MAPK signaling	TAS
R-HSA-9020702	Interleukin-1 signaling	IEA
R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	IEA
R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	IEA
R-HSA-975155	MyD88 dependent cascade initiated on endosome	IEA
R-HSA-975871	MyD88 cascade initiated on plasma membrane	IEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
27231182	A Case of Pulmonary Langerhans Cell Histiocytosis with BRAF V600E-negative and MAP2K1-posivtive Mutations Presenting as Diffuse Nodules in Chest High-resolution Computed Tomography After Smoking Cessation. (2016 Jun 5)	Li Y	Chin Med J (Engl)
24993294	Diet and lifestyle factors interact with MAPK genes to influence survival: the Breast Cancer Health Disparities Study. (2014 Sep)	Slattery ML	Cancer Causes Control
25351745	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)	Arcila ME	Clin Cancer Res
23027623	MAP kinase genes and colon and rectal cancer. (2012 Dec)	Slattery ML	Carcinogenesis
25310214	Langerhans cell histiocytosis. (2014 Oct)	Grana N	Cancer Control
29083024	Pulmonary Langerhans' cell histiocytosis in adults. (2017)	Radzikowska E	Adv Respir Med
26915300	Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease. (2016 Sep)	Kamionek M	Histopathology
25567908	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)	Drilon A	Clin Cancer Res